ONLINE MUTATION REPORT

Correlation between a specific Wilms tumour suppressor gene (*WT1*) mutation and the histological findings in Wilms tumour (WT)

R Shibata, A Hashiguchi, J Sakamoto, T Yamada, A Umezawa, J Hata

J Med Genet 2002;**39**:e83(<http://www.jmedgenet.com/cgi/content/full/39/12/e83>)

Wilms tumour (WT) is the most common malignant neoplasm of the kidney in childhood and accounts for approximately 8% of all childhood solid tumours.^{1,2} Fetal rhabdomyomatous nephroblastoma (FRN) is a histological variant of WT characterised by a predominance of rhabdomyogenic components. Clinically, WT of the FRN type presents as a huge mass in younger patients and about 30% of them have bilateral disease. The tumour rarely metastasises or shows aggressive behaviour and it has a good prognosis.³ The Wilms tumour suppressor gene (*WT1*) on chromosome 11p13 was identified in 1990 and encodes a transcriptional factor containing a domain of four zinc finger motifs.^{4,5} Schumacher *et al*⁶ reported that a germline mutation in *WT1* predisposes to the development of tumours with stromal predominant histology.⁶ We analysed germline and tumour *WT1* in seven cases of WT that were diagnosed as FRN histologically, or contained rhabdomyogenic components, and found the same mutation in five of them.

PATIENTS AND METHODS

Patients

Seven cases of WT who were treated surgically between 1998 and 2001 and contained abundant striated muscle as a stromal component histologically were studied. Cases 3, 4, 5, and 6 also had genitourinary tract malformations (table 1). Cases 3 and 6 were associated with cryptorchidism, case 4 with bilateral cryptorchidism and hypospadias, and case 5 with left ovarian dysgenesis. The tumour was bilateral in every case except case 2. None of the patients showed evidence of renal dysfunction or renal failure. Fresh tumour tissue and peripheral blood samples were obtained from all seven patients. Non-tumorous renal tissue was obtained from case 2. Informed consent was obtained from all patients or their parents.

Key points

- We analysed *WT1* in seven cases of Wilms tumour (WT). The histology of these cases mostly showed FRN or nephroblastic type tumours containing abundant mature rhabdomyomatous components with some immature metanephroblastic tissues.
- In five out of seven cases, we detected the same mutation, which was an ¹¹⁶⁸C to T substitution in zinc finger 3 and resulted in a ³⁹⁰Arg becoming a stop codon (R390X).
- Our results suggest that this specific *WT1* mutation of R390X correlates with this particular histological type of WT showing abundant rhabdomyomatous components.

Histopathological analysis

The resected tumours or biopsy specimens were fixed with 10% formalin and embedded in paraffin. Paraffin sections were stained with haematoxylin and eosin (HE), and histological subtyping of WT was performed according to the classification proposed by the Japanese Society of Pathology. We defined FRN as more than one-third of the tumour mass showing striated muscle differentiation and the nephroblastic type was defined as a tumour which showed triphasic histology containing striated muscle, but its proportion of the tumour was less than one-third.

Abbreviations: WT, Wilms tumour; *WT1*, Wilms tumour suppressor gene; FRN, fetal rhabdomyomatous nephroblastoma; LOH, loss of heterozygosity

Table 1 Clinical and histological features and the results of *WT1* mutations

Case	Age/gender	Clinical description of anomalies	Laterality	Histological subtype	Germline mutations	Tumour mutations
1	11 mth/F	(-)	Bilateral	FRN	(-)	(-)
2	1 y /M	(-)	Unilateral	FRN	(-)	1168C→T(R390X) LOH
3	11 mth/M	Cryptorchidism	Bilateral	FRN	1168C→C/T	1168C→T(R390X) Homo
4	9 mth/M	Cryptorchidism, hypospadias	Bilateral	Nephroblastic type striated muscle (+)	1168C→C/T	1168C→T(R390X) Homo
5	7 mth/F	Ovarian dysgenesis	Bilateral	FRN	1168C→C/T	1168C→T(R390X) Homo
6	1 y/M	Cryptorchidism	Bilateral	Nephroblastic type striated muscle (+)	1168C→C/T	1168C→T(R390X) LOH
7	6 mth/F	(-)	Bilateral	Nephroblastic type striated muscle (+)	(-)	(-)

Table 2 PCR and sequence primers

Exon	PCR		Sequence	
	Name	Sequence	Name	Sequence
1	WT256	AGCCAGAGCAGCAGGGAGTC	SEQ1-S	GGCATCTGGGCCAAGTTAGG
	WTEX1R2	CGGTCAAAGGGGTAGGAGA	SEQ1-A	CCTAGAGCGGAGAGTCCCTG
2	2B-S	TGGCTGTTTCAGACCACTG	SEQ2-S	TGCCCCGTCTTGCAGAGCA
	2B-A	AGAGGAGGATAGCACGGAAG	SEQ2-A	GCACGGAAGAAGGGGAGAAG
3	3B-S	CCAGGCTCAGGATCTCGTGT	SEQ3-S	ATCTCGTGTCTCCCCAACCC
	3B-A	GGCGTCTCGTGCCTCAAGA	SEQ3-A	GTGCCTCAACACCCTGCAT
4	4B-S	TGTGGAGGCTTGCACTTTCA	SEQ4-S	GAAGAAACAGTTGTATTATTTG
	4B-A	GCCCTTTCTCTAAACTGT	SEQ4-A	ATGGTTCAACAGGTATAAGTTACT
5	5B-S	TCACTGGATTCTGGGATCTG	SEQ5-S	CTGGGATCTGGGGGGCTGCCA
	5B-A	AGTCCTAACTCTGCATTGC	SEQ5-A	CCCCAGGTGCCAGTCAGCAAGG
6	6B-S	AAAACCATCATTCCCTCCTG	SEQ6-S	TTCCAAATGGCGACTGTGAGC
	6B-A	CAAAGAGTCCATCAGTAAGG	SEQ6-A	GGTAAGTAGGAAGAGGCAGTGC
7	7F-S	GTGCTCACTCTCCCTCAAGA	SEQ7-S	TCCCTCAAGACCTACGTGAATGTT
	7F-A	GTGAGAGCCTGGAAAAGGAGC	SEQ7-A	TTGAACCATGTTGCCCAAGACTGG
8	8-S	AGATCCCCTTTCCAGTATC	SEQ8-S	AGATCCCCTTTCCAGTATC
	8C'-A	CAACAACAAAGAGAATCA	SEQ8-A	AAATCAACCCTAGCCCAAGG
9	9C-S	AAGTCAGCCTTGTGGGCCTC	SEQ9-S	CCCACATTGGTTAGGGCCGAGGCTA
	9C-A	TTCCAATCCCCTCTCATCAC	SEQ9-A	TAGGGCCGAGGCTAGACCTTCTCT
10	10C-S	CACCTCGGGCCTTGATAGTTG	SEQ10-S	TTTCCAATCCCCTCTCATCAC
	10C-A	GTCAGACTTGAAAGCAGTTC	SEQ10-A	TGTGCCTGTCTCTTTGTTGC

DNA preparation

Mononuclear cells were isolated from the patients' peripheral blood. Tumour tissue and non-tumorous renal tissue were stored at -80°C until used. DNA was extracted from leucocytes and tumour tissue by the SDS-proteinase K method with slight modifications, as described previously.⁷ Amplification of exons 1 to 10 was performed by PCR. Direct sequencing of the PCR products was performed with a MegaBACE 1000 DNA Sequencing System (Amersham Biosciences, Florida, USA).

The precise methods have been described previously.⁸ The PCR and sequence primers used are shown in table 2.

Polymorphic analysis of WT1

We used a polymorphic marker, WT1-P, to investigate whether the mutation detected in *WT1* in the tumour cells was homozygous or hemizygous as a result of loss of heterozygosity (LOH). This marker detects a GT polymorphism in the 3' non-coding region of exon 10 of *WT1*.⁹ We used primers WT1P2-1

Figure 1 Haematoxylin and eosin section. (A) Case 5. Immature striated muscle is the predominant stromal element. This is the typical histological appearance of FRN. (B) Case 6. Nodular blastemal pattern of the nephroblastic type of WT. A small number of tubular structures are present in the nodule. (C) Case 6. Striated muscle cells are seen as stromal components in case 6.

Figure 2 Results of DNA sequence analyses of germline (A) and tumour samples (B) with a *WT1* mutation. (A) A heterozygous point mutation, 1168C/T, was found in exon 9 in the germline of the patient and her father. (B) A point mutation, 1168C/T, changes the codon for ³⁹⁰Arg into a stop codon in the tumours.

(5'-CTTACTGGGTGAGGAAATCC-3') and WT1P2-2 (5'-ACAGTAATTCAAGCAACGG-3') and an ALF win Fragment Analyzer (Amersham Biosciences). All procedures were approved by the Ethical Committee of the Keio University School of Medicine.

RESULTS

The clinical and pathological features and the results of the *WT1* mutations are summarised in table 1. All seven patients were under 1 year of age. Cases 3, 4, 5, and 6 were complicated

by congenital genitourinary malformations. The WT was bilateral in every case except case 2. Cases 1, 2, 3, and 5 showed the typical histological features of FRN (fig 1A). Cases 4, 6, and 7 were the nephroblastic type (fig 1B) and contained striated muscle components (fig 1C).

DNA sequence analyses indicated the same constitutional point mutations in exon 9 in cases 3, 4, 5, and 6. The mutation was a 1168C-T substitution in zinc finger 3 and resulted in a ³⁹⁰Arg becoming a stop codon (R390X). There was a heterozygous mutation in the same codon in the germline of cases 3, 4, 5, and 6 (fig 2). Case 2 showed mutation R390X in the tumour, but no mutations were found in the germline. No *WT1* mutations were detected in cases 1 or 7.

The results of the polymorphic analysis of 11p13 are also summarised table 1. The germline in case 5 contained 124 bp and 132 bp bands at WT1-P. These bands were also detected in the bilateral tumours (fig 3A), and we concluded that the *WT1* mutation in the tumours were heterozygous. Cases 3 and 4 also showed heterozygous mutations in tumour tissue (data not shown). DNA isolated from mononuclear cells and the non-tumorous renal tissue of case 2 contained 124 bp and 130 bp bands at WT1-P. The tumour showed only a 124 bp band and it was concluded to show LOH (fig 3B). Case 6 also showed LOH in tumour tissue at WT1-P (data not shown).

DISCUSSION

We found the same mutation of *WT1* in five of the seven cases of WT that were classified as FRN histologically or contained abundant rhabdomyogenic components. Our findings suggested that this specific *WT1* mutation, R390X, is correlated with the histological features of WT.

Figure 3 Polymorphic analysis of *WT1*, detecting a GT polymorphism in the 3' non-coding region of exon 10. M, external markers of 100 bp and 150 bp. (A) Case 5. (a) Germline of the patient; (b) left tumour sample; (c) right tumour sample. A 124 bp and 132 bp band were identified in the germline cells (a) and the both tumour samples (b and c). Lanes a, b, and c show 100 bp and 150 bp bands as internal markers. (B) Case 2. (a) Germline of the patient; (b) non-tumorous renal tissue; (c) tumour sample. A 124 bp and 130 bp band were identified in the germline cells (a) and the non-tumorous renal tissue (b). However, only the 124 bp band was detected in the tumour sample (c). Lanes a, b, and c show 100 bp and 150 bp bands as internal markers.

Cases 3, 4, 5, and 6 were found to have the same constitutional point mutations, a change from 1168C to T in zinc finger 3, resulting in ³⁹⁰Arg becoming a stop codon. Case 2 had the R390X mutation in the tumour. During translation, this nonsense mutation leads to protein truncation, and the result is that the last zinc finger necessary for DNA binding of *WT1* is missing. Interrupted DNA binding to the target genes of *WT1* with loss of the last zinc finger has previously been shown by electrophoretic mobility shift assays.¹⁰ Loss of *WT1* function has been reported to be the underlying cause of tumour development. Miyagawa *et al*¹¹ reported that loss of *WT1* function leads to ectopic myogenesis in WT and suggested that normal expression of *WT1* might prevent the metanephric-mesenchymal stem cells of the kidney from differentiating into skeletal muscle.¹¹ Three of the five cases that had the *WT1* mutations, cases 2, 3, and 5, were classified as FRN. Cases 4 and 6 were the nephroblast type and contained striated muscle as stromal components. It could not be concluded that all WTs with the R390X mutation are FRN histologically, but the results at least suggested a correlation between this mutation and rhabdomyomatous histology of WT.

In earlier studies, mutation R390X had been found in patients with sporadic unilateral WT, in a patient with bilateral WT, and in a patient with WT associated with urogenital malformation.¹²⁻¹⁴ This mutation has also been detected in a patient with acute promyelocytic leukaemia¹⁵ and a patient with an isolated genital malformation without WT.¹⁶ However, the histological findings in the WTs with the R390X mutation have not been published previously. Histological information in these cases would show whether our hypothesis is more likely or not.

Schumacher *et al*⁶ reported that a germline mutation in *WT1* predisposes to the development of tumours with predominantly stromal histology.⁶ Case 2 had no germline mutation; however, since Nakadate *et al*¹⁷ reported that not only germinal *WT1* mutation/deletion but somatic *WT1* deletion/mutation correlated with the predominantly stromal histology,¹⁷ the somatic mutation appears to be associated with the histology in case 2.

Some authors have reported *WT1* mutations in WT patients with congenital genitourinary malformations in the absence of renal disorders.^{6, 18-20} Huff *et al*²¹ hypothesised that the truncated protein resulting from *WT1* mutation is non-functional and causes genitourinary malformation by a dose effect of decreasing normal *WT1* protein. Cases 3, 4, 5, and 6, which had *WT1* mutations, exhibited congenital genitourinary malformations, suggesting that the loss of *WT1* function may cause genitourinary malformation.

Bilateral WT is explained by the two hit inactivation mechanism of a tumour suppressor gene, as proposed by Knudson and Strong.^{6, 22, 23} Cases 3, 4, 5, and 6 presented with bilateral disease, and a heterozygous mutation was detected in their germline and either LOH (case 6) or a homozygous mutation (cases 3, 4, and 5) was found in their tumour specimens. These findings support the two hit inactivation model in bilateral WT. Based on the results of this study, the loss of *WT1* expression caused by the R390X mutation appears to be related to the histological findings, genitourinary malformations, and tumorigenesis, at least in bilateral WT. The tumours in cases 1 and 7 contained rhabdomyomatous components and had bilateral disease, but no *WT1* mutation was detected in them. They had no evidence of congenital genitourinary malformations. Another mechanism may be related to the tumorigenesis of bilateral WT without congenital genitourinary malformations.

CONCLUSION

We found that a specific *WT1* mutation of R390X correlates with the histology of WT. WTs with this mutation tend to be FRN or to contain rhabdomyogenic components histologically. This mutation appears to be strongly correlated with not only the histological features but with tumorigenesis in bilateral WTs

with congenital genitourinary malformations. However, this report is on only seven cases and we need to investigate more cases of unilateral FRN or cases with FRN but no congenital abnormalities to see if they show *WT1* mutation or not.

ACKNOWLEDGEMENTS

We thank Drs Y Tanaka (Kanagawa Children's Medical Centre), Y Nakatani and Y Inayama (Hospital of Yokohama City University), K Hashizume and Y Kanamori (University of Tokyo Faculty of Medicine), J Miyauchi and Y Tsunematsu (National Centre for Child Health and Development), Y Hayashi (Tohoku University School of Medicine), H Shima and N Konishi (Hyogo College of Medicine), and Y Ogawa (Saitama Children's Medical Centre) for providing samples and clinical data. We thank Miss Y Nakamura for her technical assistance. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (11557021, 13470053, 13022264 and 11167274), as well as Cancer Research Grants from the Ministry of Health, Labour and Welfare (9-14, 10D-1).

Authors' affiliations

R Shibata, A Hashiguchi, T Yamada, A Umezawa, J Hata, Department of Pathology, Keio University School of Medicine, Tokyo, Japan

J Sakamoto, Department of Paediatric Surgery, University of Tokyo Faculty of Medicine, Tokyo, Japan

J Hata, National Research Institute for Child Health and Development, Tokyo, Japan

Correspondence to: Dr J Hata, National Research Institute for Child Health and Development, 3-35-31 Taishido Setagaya-ku, Tokyo 154-8567, Japan; jhata@nch.go.jp

REFERENCES

- Coppes MJ, Pritchard-Jones K. Principles of Wilms' tumor biology. *Urol Clin North Am* 2000;**27**:423-33.
- Lee SB, Haber DA. Wilms tumor and the *WT1* gene. *Exp Cell Res* 2001;**264**:74-99.
- Wigger HJ. Fetal rhabdomyomatous nephroblastoma-a variant of Wilms' tumor. *Hum Pathol* 1976;**7**:613-23.
- Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose AE, Kral A, Yeger H, Lewis WH, Jones C, Housman DE. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. *Cell* 1990;**60**:509-20.
- Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GAP. Homozygous deletion in Wilms' tumors of a zinc-finger gene identified by chromosome jumping. *Nature* 1990;**343**:774-8.
- Schumacher V, Schneider S, Figge A, Wildhardt G, Harms H, Schmidt D, Weirich A, Ludwig R, Royer-Pokora B. Correlation of germ-line mutations and two-hit inactivation of the *WT1* gene with Wilms tumors of stromal-predominant histology. *Proc Natl Acad Sci USA* 1997;**94**:3972-7.
- Kikuchi H, Akasaka Y, Kurosawa Y, Yoneyama H, Kato S, Hata J. A critical mutation in both *WT1* alleles is not sufficient to cause Wilms' tumor. *FEBS Lett* 1995;**360**:26-8.
- Takata A, Kikuchi H, Fukuzawa R, Ito S, Honda M, Hata J. Constitutional *WT1* correlates with clinical features in children with progressive nephropathy. *J Med Genet* 2000;**37**:698-701.
- Tadokoro K, Oki N, Sakai A, Fujii H, Ohshima A, Nagafuchi S, Inoue T, Yamada M. PCR detection of 9 polymorphisms in the *WT1* gene. *Hum Mol Genet* 1993;**2**:2205-6.
- Little M, Holmes G, Bickmore W, Heyningen V, Hastie N, Wainwright B. DNA binding capacity of the *WT1* protein is abolished by Denys-Drash syndrome *WT1* point mutations. *Hum Mol Genet* 1995;**4**:351-8.
- Miyagawa K, Kent J, Moore A, Charlier JP, Little MH, Williamson KA, Kelsey A, Brown KW, Hassam S, Briner J, Hayashi Y, Hirai H, Yazaki Y, Heyningen V, Hastie ND. Loss of *WT1* function leads to ectopic myogenesis in Wilms' tumor. *Nat Genet* 1998;**18**:15-7.
- Little MH, Prosser J, Condie A, Smith PJ, Heyningen V, Hastie ND. Zinc finger point mutations within the *WT1* gene in Wilms tumor patients. *Proc Natl Acad Sci USA* 1992;**89**:4791-5.
- Gessler M, Konig A, Arden K, Grundy P, Orkin S, Sallan S, Peters C, Ruyle S, Mandell J, Li F, Cavenee W, Bruns G. Infrequent mutation of the *WT1* gene in 77 Wilms' tumors. *Hum Mutat* 1994;**3**:212-22.
- Little M, Wells C. A clinical overview of *WT1* gene mutations. *Hum Mutat* 1997;**9**:209-25.
- King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms' tumor gene *WT1* in leukemias. *Blood* 1996;**87**:2171-9.
- Kohler B, Schumacher V, l'Allemand D, Royer-Pokora B, Grutters A. Germline Wilms tumor suppressor gene (*WT1*) mutation leading to isolated genital malformation without Wilms tumor or nephropathy. *J Pediatr* 2001;**138**:421-4.
- Nakadate H, Yokomori K, Watanabe N, Tsuchiya T, Namiki T, Kobayashi H, Suita S, Tsunematsu Y, Horikoshi Y, Hatae Y, Endo M,

- Kodama Y, Eguchi H, Toyoda Y, Kikuta A, Kobayashi R, Kaneko Y. Mutations/deletions of the WT1 gene, loss of heterozygosity on chromosome arms 11p and 11q, chromosome ploidy and histology in Wilms' tumors in Japan. *Int J Cancer* 2001;**94**:396-400.
- 18 **Pelletier J**, Bruening W, Li FP, Haber DA, Glaser T, Housman DE. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. *Nature* 1991;**353**:431-4.
- 19 **Kohler B**, Schumacher V, Schulte-Overberg U, Biewald W, Lennert T, l'Allemand D, Royer-Pokora B, Gruters A. Bilateral Wilms tumor in a boy with severe hypospadias and cryptorchidism due to a heterozygous mutation in the WT1 gene. *Pediatr Res* 1999;**45**:187-90.
- 20 **Sakamoto J**, Takata A, Fukuzawa R, Kikuchi H, Sugiyama M, Kanamori Y, Hashizume K, Hata J. A novel wt1 gene mutation associated with Wilms' tumor and congenital male genitourinary malformation. *Pediatr Res* 2001;**50**:337-44.
- 21 **Huff V**. Genotype/phenotype correlations in Wilms' tumor. *Med Pediatr Oncol* 1996;**27**:408-14.
- 22 **Knudson AG Jr**, Strong LC. Mutation and cancer: a model for Wilms' tumor of the kidney. *J Natl Cancer Inst* 1972;**48**:313-24.
- 23 **Huff V**, Miwa H, Haber DA, Call KM, Housman D, Strong LC, Saunders GF. Evidence for WT1 as a Wilms tumor (WT) gene: intragenic germinal deletion in bilateral WT. *Am J Hum Genet* 1991;**48**:997-1003.